Grafton, WI (November 6, 2012) – Cedarburg Hauser Pharmaceuticals (CHP), an experienced contract development and manufacturing organization (CDMO), has announced the appointment of John K. Lynch, Ph.D. as its Chief Scientific Officer (CSO).
Dr. Lynch has served as Cedarburg Hauser’s Director of Research and Development for the last three years, where he oversaw development projects and led a staff of scientists. Prior to joining Cedarburg Hauser, Dr. Lynch spent 15 years at Abbott Laboratories, working on a variety of process development and medicinal chemistry projects.
“Dr. Lynch’s promotion is well deserved” says Cedarburg Hauser’s CEO, Tony Laughrey. “In his time at Cedarburg Hauser, John has successfully led Cedarburg Hauser’s research and development efforts and is the ideal person to head-up the company’s scientific operations.”
“Dr. Lynch is a very talented chemist with a real aptitude for identifying problematic areas in an industrial process and optimizing reaction conditions “ added Chuck Boland, Executive Vice President. “These skills have allowed Cedarburg Hauser to save our clients time and money, increasing yields and improving performance.”
In his new role, Dr. Lynch will oversee all scientific operations including the process development, R&D and analytical groups. Dr. Lynch holds a Ph.D. in organic chemistry from Harvard University where he studied under Prof. David Evans, and also holds a B.S. from the University of Wisconsin – Madison.
About Cedarburg Hauser Pharmaceuticals
Cedarburg Hauser Pharmaceuticals is an experienced, contract development and manufacturing organization (CDMO), specializing in small molecule active pharmaceutical ingredients (API) and pharmaceutical intermediates. Cedarburg Hauser leverages a talented group of scientists and supporting -staff, as well as a centralized approach to project management, to ensure on-time and on-budget completion of projects involving the development, scale-up, and manufacturing of complex APIs.